Elsevier

Biomaterials

Volume 32, Issue 34, December 2011, Pages 8783-8796
Biomaterials

Biocompatibility and biofilm inhibition of N,N-hexyl,methyl-polyethylenimine bonded to Boston Keratoprosthesis materials

https://doi.org/10.1016/j.biomaterials.2011.08.010Get rights and content

Abstract

The biocompatibility and antibacterial properties of N,N-hexyl,methyl-polyethylenimine (HMPEI) covalently attached to the Boston Keratoprosthesis (B-KPro) materials was evaluated. By means of confocal and electron microscopies, we observed that HMPEI-derivatized materials exert an inhibitory effect on biofilm formation by Staphylococcus aureus clinical isolates, as compared to the parent poly(methyl methacrylate) (PMMA) and titanium. There was no additional corneal epithelial cell cytotoxicity of HMPEI-coated PMMA compared to that of control PMMA in tissue cultures in vitro. Likewise, no toxicity or adverse reactivity was detected with HMPEI-derivatized PMMA or titanium compared to those of the control materials after intrastromal or anterior chamber implantation in rabbits in vivo.

Introduction

Indwelling prosthetic devices have been critical in saving numerous lives and they have enhanced the quality of life for even more patients [1]. Yet the presence of an indwelling foreign body both predisposes to, and complicates the eradication of, infections, often with biofilm formation [2]. Device-related biofilm infections account for some 60% of all hospital-associated infections [3] and add about $5 billion per year to U.S. hospital costs [4]. Biofilms, heterogenous collections of bacteria often encased by a secreted matrix called extracellular polymeric substance (EPS) [5], adhere strongly to surfaces, are resistant to antibiotics and other biocides, and are protected from host immune defenses [6]. The risk of a biofilm-associated medical device infection depends on its location, with any implantable device that translocates from the surface of the body (skin, cornea) into a sterile body site (blood, urine, intraocular) being at greater risk [2], [7].

The Boston Keratoprosthesis (B-KPro) is an artificial cornea that is a treatment option for corneal disorders not amenable to standard penetrating keratoplasty (corneal transplantation) [8]. The B-KPro has the shape of a collar button and consists of a transparent medical-grade poly(methyl methylacrylate) (PMMA) front plate with a stem, that houses the optical portion of the device, and a back plate with holes composed of either PMMA or medical-grade titanium. During implantation, the device is assembled with a donor corneal graft positioned between the front and back plates with extension of the optic stem into the anterior chamber of the eye; a titanium C-ring locks the assembly (Fig. 1A–C) [9]. Its postoperative management includes the continuous wearing of a soft contact lens to prevent ocular surface dehydration and tissue melt [10]. Daily low-dose topical antibiotic prophylaxis is required [11], as well as low-dose topical steroids in many patients [9]. While the use of life-long daily antibiotic prophylaxis to prevent infection has been effective, long-term medication adherence and emergence of resistant organisms continue to be concerns, especially in the developing world [12].

Thus there is a great need for keratoprostheses and other implantable medical devices that inherently resist bacterial infection long-term. Most biocidal products depend on a timed release of antibiotics, heavy metal ions (notably silver), or other biocides. Once all biocide has been released, the antimicrobial activity ends, leaving foreign material in situ; consequently, the overall long-term benefit of antibiotic-impregnated materials remains unclear [13]. Given the large health care costs of medical-device and hospital-acquired infections [4], non-toxic materials that effectively and permanently limit microbial adherence and viability are very much needed.

It would be most desirable to permanently attach coatings onto PMMA and other currently used prosthetic materials that either prevent adherence of bacteria or kill them on contact, thereby inhibiting the formation of biofilms. Recently, non-leaching, long-chained hydrophobic polycations that can be attached covalently to the materials’ surfaces and render them strongly antimicrobial have been developed [14], [15]. Specifically, immobilized N,N-hexyl,methyl-polyethylenimine (HMPEI) (Fig. 1D) has broad antibacterial, antifungal, and antiviral properties [16], [17], [18], [19].

Herein we assess HMPEI covalently attached to PMMA and titanium materials used in the construction of the B-KPro. Antimicrobial efficacy against hyperbiofilm-forming clinical isolates of Staphylococcus aureus and in vitro cell cytotoxicity using immortalized human corneal epithelial cells were investigated. In vivo biocompatibility studies with new ocular models in the rabbit comparing HMPEI-derivatized and parent PMMA and titanium, as well as the B-KPro with applicability to other implantable medical devices, were examined.

Section snippets

Materials

Laboratory chemicals, branched 750-kDa PEI [19], 500-kDa poly(2-ethyl-2-oxazoline), and organic solvents were from Sigma–Aldrich Chemical Co. (St. Louis, MO). Linear PEI (217 kDa) was prepared by deacylation of poly(2-ethyl-2-oxazoline) as previously described [19].

The Boston Keratoprosthesis (B-KPro) parent materials were medical-grade poly(methyl methacrylate) (PMMA) (Spartech Townsend, Pleasant Hill, IA) and titanium (Ti) 6-4 ELI (Dynamet, Washington, PA) processed by J.G. Machine Co

In vitro studies

Since there is suggestive evidence that ocular infection may be caused by a subset of organisms that possess virulence traits [20], [21], [22] and because media composition affects in vitro biofilm production [33], we evaluated S. aureus laboratory strains and clinical isolates for biofilm production under various media and growth conditions (Table 1). As others [34], we found that S. aureus ocular isolates formed biofilms variably under different conditions. We selected those ocular-associated

Discussion

Immobilized HMPEI exerts its antimicrobial effects by long hydrophobic polycationic chains that are able to penetrate and lyse the cell membranes/walls of microorganisms [14], [15]. This contact-dependent killing has been demonstrated for planktonic bacteria, as well as viruses and fungi [17], [18], [19], but heretofore not for bacterial biofilms that are the major cause of device-associated infections [3] and naturally resistant to antimicrobial agents [5]. Using large inocula (>107) of S.

Conclusions

HMPEI covalently attached to B-KPro materials inhibits biofilm formation by S. aureus. The immobilized hydrophobic polycation confers no additional toxicity or reactivity compared to the control in vitro or in vivo in enucleated eyeballs in the adjacent corneal stroma, anterior chamber, or iris. Because it is easily observable and the prosthetic material can be easily removed or exchanged, the B-KPro may represent an ideal format for testing these antimicrobial coatings in humans.

Acknowledgments

We thank Therese F. Labrecque, M. Susan Parker, Rick P. Boody, David W. Sheridan, and Nancy Sutcliffe (MEEI Henry Whittier Porter Bacteriology Laboratory); Donald Pottle (SERI Confocal Microscopy facility); Sandra J. Spurr-Michaud (SERI - tissue culture); Norman A. Michaud and Valdemar Araujo (MEEI Core Morphology); John M. Graney (JG Machine, Woburn, MA); Kathryn V. Martin (MEEI animal research assistance); Marcus Rauch, Susan R. Heimer, James Chodosh, Roberto Pineda II, and the MEEI B-KPro

References (39)

  • K. Lewis et al.

    Surpassing nature: rational design of sterile-surface materials

    Trends Biotechnol

    (2005)
  • K.R. Wilhelmus

    The Draize eye test

    Surv Ophthalmol

    (2001)
  • J. Butany et al.

    Analysis of prosthetic cardiac devices: a guide for the practicing pathologist

    J Clin Pathol

    (2005)
  • A.S. Baker et al.

    Ocular infections

  • R.O. Darouiche

    Treatment of infections associated with surgical implants

    N Engl J Med

    (2004)
  • R.D. Scott

    The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention

    (2009)
  • J.W. Costerton et al.

    Bacterial biofilms: a common cause of persistent infections

    Science

    (1999)
  • C.A. Fux et al.

    Survival strategies of infectious biofilms

    Trends Microbiol

    (2005)
  • I. Behlau et al.

    Microbial biofilms in ophthalmology and infectious diseases

    Arch Ophthalmol

    (2008)
  • C.H. Dohlman et al.

    Introduction to the use of the Boston keratoprosthesis

    Expert Rev Ophthalmol

    (2006)
  • M. Harissi-Dagher et al.

    Importance of nutrition to corneal grafts when used as a carrier of the Boston keratoprosthesis

    Cornea

    (2007)
  • C.H. Dohlman et al.

    Protection of the ocular surface after keratoprosthesis surgery: the role of soft contact lenses

    CLAO J

    (2002)
  • M.L. Durand et al.

    Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis

    Cornea

    (2009)
  • R. Pineda et al.

    Prospective evaluation of sustaining the Boston Keratoprosthesis in the developing world: a pilot study

    Invest Ophthalmol Vis Sci

    (2009)
  • E. Bennett-Guerrero et al.

    For the SWIPE 2 Trial Group, Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery

    N Engl J Med

    (2010)
  • A.M. Klibanov

    Permanently microbicidal materials coatings

    J Mater Chem

    (2007)
  • N.M. Milovic et al.

    Immobilized N-alkylated polyethylenimine avidly kills bacteria by rupturing cell membranes with no resistance developed

    Biotechnol Bioeng

    (2005)
  • J. Lin et al.

    Insights into bactericidal action of surface-attached poly (vinyl-N-hexylpyridium) chains

    Biotechnol Lett

    (2002)
  • J. Lin et al.

    Mechanism of bactericidal and fungicidal activities of textiles covalently modified with alkylated polyethylenimine

    Biotechnol Bioeng

    (2003)
  • Cited by (0)

    View full text